Riskpilot← Back to searchSign inGet full accessWEBPHARMA SPT AS
ASActiveOrg 981578880Karoline Kristiansens Vei 5, 0661 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 200015 employees
Revenue 2024
NOK 144,3M
+15% vs 2023
EBITDA margin
0.5%
-48% vs 2023
Equity ratio
7.5%
Financial strength
Net profit 2024
NOK -462K
-358% vs 2023
| Revenue | NOK 144,3M | +15% |
| EBITDA | NOK 755K | -48% |
| Net profit | NOK -462K | -358% |
| Total assets | NOK 25,7M | +1% |
| Equity | NOK 1,9M | -19% |
| Employees | 15 | — |
Legal name
WEBPHARMA SPT AS
Org number
981578880
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
5. april 2000
Share capital
NOK 1 188 264
Employees
15 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Utvikle innovative systemløsninger innen områdene teknologi, internett baserte tjenester og system for elektronisk handel. Selskapet skal kunne levere en eller flere produktløsninger. Selskapet skal kunne lisensiere ut systemløsninger, og rettighetsbeskytte de varemerker og produkter som selskapet utvikler. Selskapet vil kunne inneha produktrettigheter, utvikle egne legemidler, drive import og eksport av legemidler, utvikle systemer for bedriftshelsetjeneste, samt å kunne investere i annen virksomhet, og hva hermed står i forbindelse innen investering og utvikling av selskaper.
Address
Karoline Kristiansens Vei 5, 0661 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20 497 | 22 140 | 24 691 | 28 957 | 37 169 | 38 168 | 42 333 | 54 216 | 60 493 | 82 556 | 83 597 | 84 529 | 96 122 | 111 497 | 114 816 | 125 942 | 144 300 |
| Staff expenses | −1 384 | −1 132 | −1 246 | −1 323 | −1 659 | −2 037 | −2 164 | −2 844 | −2 998 | −4 258 | −4 502 | −4 448 | −5 313 | −6 327 | −5 698 | −6 498 | −6 725 |
| EBITDA | −581 | −70 | 791 | 675 | 522 | 363 | 868 | 979 | 1 171 | 1 238 | 1 855 | 1 568 | 1 998 | 2 532 | 866 | 1 458 | 755 |
| Depreciation & amort. | −436 | −578 | −669 | −612 | −510 | −585 | −745 | −909 | −1 009 | −1 030 | −1 461 | −1 270 | −1 613 | −2 074 | −1 702 | −1 159 | −1 139 |
| EBIT | −1 018 | −648 | 122 | 63 | 11 | −222 | 123 | 70 | 162 | 208 | 394 | 299 | 385 | 457 | −836 | 299 | −384 |
| Net financials | 10 | 3 | 8 | 16 | 6 | −12 | −1 | −10 | −82 | 14 | −8 | −10 | −44 | −10 | −29 | −120 | −78 |
| Profit before tax | −1 008 | −645 | 131 | 79 | 17 | −234 | 122 | 60 | 80 | 222 | 386 | 289 | 341 | 447 | −865 | 179 | −462 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −1 008 | −645 | 131 | 79 | 17 | −234 | 122 | 60 | 80 | 222 | 386 | 289 | 341 | 447 | −865 | 179 | −462 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 4 420 | 5 192 | 4 942 | 6 661 | 6 830 | 7 037 | 8 084 | 9 960 | 10 241 | 12 340 | 12 905 | 17 461 | 18 261 | 25 897 | 26 449 | 25 535 | 25 707 |
| Equity | 402 | 1 139 | 1 270 | 1 349 | 1 366 | 1 132 | 1 254 | 1 314 | 1 393 | 1 615 | 2 001 | 2 290 | 2 631 | 3 078 | 2 213 | 2 392 | 1 930 |
| Long-term debt | 5 | 0 | 0 | 0 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Short-term debt | 4 013 | 4 048 | 3 667 | 5 307 | 5 458 | 5 900 | 6 825 | 8 641 | 8 842 | 10 720 | 10 899 | 15 166 | 15 626 | 22 814 | 24 230 | 23 138 | 23 772 |
| Total debt | 4 018 | 4 048 | 3 667 | 5 307 | 5 463 | 5 905 | 6 830 | 8 646 | 8 847 | 10 725 | 10 904 | 15 171 | 15 631 | 22 819 | 24 235 | 23 143 | 23 777 |
EBITDA margin
0.5%
This company
15.8%
Market median
-97% vs market
20082024
Equity ratio
7.5%
This company
38.2%
Market median
-80% vs market
20082024
Return on equity
-23.9%
This company
18.4%
Market median
-230% vs market
20082024
Net profit margin
-0.3%
This company
8.1%
Market median
-104% vs market
20082024
Asset turnover
5.61×
This company
1.12×
Market median
+401% vs market
20082024
Debt / equity
12.32×
This company
0.62×
Market median
-1887% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Sesam Invest As | Company | 47.9% | 47.9% | 2023 |
As Selvaag Invest | Company | 30.0% | 30.0% | 2023 |
Altea As | Company | 6.0% | 6.0% | 2023 |
Vefring Invest As | Company | 4.5% | 4.5% | 2023 |
| Individual | 2.4% | 2.4% | 2022 | |
| Individual | 2.4% | 2.4% | 2023 | |
| Individual | 2.4% | 2.4% | 2023 | |
Ulle Holding As | Company | 1.6% | 1.6% | 2023 |
| Individual | 1.1% | 1.1% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Mulholland Holding As
WEBPHARMA SPT AS Board members of WEBPHARMA SPT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rune Ingve Fløgstad | Board of Directors | 0 companies |
| Hans Ragnar Preus | Board of Directors | 0 companies |